Mylan N.V. (NASDAQ:MYL)‘s stock had its “hold” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report issued on Friday. They presently have a $34.00 target price on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 5.92% from the company’s previous close.

Several other analysts also recently weighed in on the stock. BidaskClub upgraded shares of Mylan N.V. from a “strong sell” rating to a “sell” rating in a report on Thursday. ValuEngine downgraded shares of Mylan N.V. from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Argus downgraded shares of Mylan N.V. from a “buy” rating to a “hold” rating and dropped their target price for the company from $47.59 to $29.39 in a report on Tuesday, August 22nd. Mizuho reiterated a “buy” rating and issued a $37.00 target price (down previously from $53.00) on shares of Mylan N.V. in a report on Sunday, August 20th. Finally, Citigroup Inc. upgraded shares of Mylan N.V. from a “neutral” rating to a “buy” rating and lifted their target price for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $43.43.

Shares of Mylan N.V. (NASDAQ MYL) traded up 0.60% during trading on Friday, reaching $32.10. The company’s stock had a trading volume of 4,134,692 shares. The company has a 50 day moving average of $33.38 and a 200 day moving average of $37.95. The company has a market cap of $17.21 billion, a PE ratio of 25.95 and a beta of 1.31. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.

Mylan N.V. (NASDAQ:MYL) last posted its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by $0.08. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. During the same quarter last year, the business posted $1.16 EPS. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, analysts anticipate that Mylan N.V. will post $4.52 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Mylan N.V. (MYL) Stock Rating Reaffirmed by Cantor Fitzgerald” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/08/mylan-n-v-myl-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

Institutional investors have recently added to or reduced their stakes in the company. First Personal Financial Services lifted its position in shares of Mylan N.V. by 33.2% during the 1st quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock worth $107,000 after purchasing an additional 681 shares during the last quarter. Global X Management Co. LLC lifted its position in shares of Mylan N.V. by 91.6% during the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock worth $118,000 after purchasing an additional 1,441 shares during the last quarter. Ropes Wealth Advisors LLC purchased a new stake in shares of Mylan N.V. during the 1st quarter worth $136,000. TLP Group LLC purchased a new stake in shares of Mylan N.V. during the 1st quarter worth $200,000. Finally, Doliver Capital Advisors LP purchased a new stake in shares of Mylan N.V. during the 2nd quarter worth $201,000. 71.97% of the stock is owned by institutional investors and hedge funds.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.